Jpmorgan Chase & CO Actinium Pharmaceuticals, Inc. Transaction History
Jpmorgan Chase & CO
- $1.14 Trillion
- Q2 2024
A detailed history of Jpmorgan Chase & CO transactions in Actinium Pharmaceuticals, Inc. stock. As of the latest transaction made, Jpmorgan Chase & CO holds 13,895 shares of ATNM stock, worth $24,455. This represents 0.0% of its overall portfolio holdings.
Number of Shares
13,895
Previous 11,784
17.91%
Holding current value
$24,455
Previous $92,000
10.87%
% of portfolio
0.0%
Previous 0.0%
Shares
5 transactions
Others Institutions Holding ATNM
# of Institutions
79Shares Held
7.28MCall Options Held
96.6KPut Options Held
70.5K-
Black Rock Inc. New York, NY1.88MShares$3.3 Million0.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA1.48MShares$2.6 Million0.0% of portfolio
-
Geode Capital Management, LLC Boston, MA666KShares$1.17 Million0.0% of portfolio
-
State Street Corp Boston, MA610KShares$1.07 Million0.0% of portfolio
-
Marshall Wace, LLP London, X0256KShares$450,6050.0% of portfolio
About Actinium Pharmaceuticals, Inc.
- Ticker ATNM
- Exchange NYSE
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 25,184,700
- Market Cap $44.3M
- Description
- Actinium Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing therapies for bone marrow transplant (BMT) or a type of cellular therapy, and for other adoptive cell therapies. Its lead product candidate, I-131 apamistamab (Iomab-B) that is in a pivotal Phase III clinical trial for elderly re...